Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1801 Views
-
Last post by Tif
-
- 5 Replies
- 778 Views
-
Last post by DIM
-
- 1 Replies
- 506 Views
-
Last post by Leonard
-
- 2 Replies
- 1200 Views
-
Last post by DIM
-
- 0 Replies
- 1404 Views
-
Last post by Tif
-
- 0 Replies
- 2170 Views
-
Last post by Tif
-
- 0 Replies
- 1571 Views
-
Last post by Tif
-
- 1 Replies
- 1177 Views
-
Last post by 1eye
-
- 4 Replies
- 2613 Views
-
Last post by NHE